Driessen, Christoph

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 11.

Journal Article

Novak, Urban; Fehr, Martin; Schär, Sämi; Dreyling, Martin; Schmidt, Christian; Derenzini, Enrico; Zander, Thilo; Hess, Georg; Mey, Ulrich; Ferrero, Simone; Mach, Nicolas; Boccomini, Carola; Böttcher, Sebastian; Voegeli, Michèle; Cairoli, Anne; Ivanova, Vanesa-Sindi; Menter, Thomas; Dirnhofer, Stefan; Scheibe, Bernhard; Gadient, Sandra; ... (2023). Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). EClinicalMedicine, 64, p. 102221. Elsevier 10.1016/j.eclinm.2023.102221

Zander, Thilo; Pabst, Thomas; Schär, Sämi; Aebi, Stefan; Mey, Ulrich; Novak, Urban; Lerch, Erika; Rhyner Agocs, Gaëlle; Goede, Jeroen; Maniecka, Zuzanna; Hayoz, Stefanie; Rüfer, Axel; Renner, Christoph; Driessen, Christoph (2023). Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia, 37(3), pp. 699-701. Springer Nature 10.1038/s41375-023-01809-z

Nuñez, Nicolas Gonzalo; Berner, Fiamma; Friebel, Ekaterina; Unger, Susanne; Wyss, Nina; Gomez, Julia Martinez; Purde, Mette-Triin; Niederer, Rebekka; Porsch, Maximilian; Lichtensteiger, Christa; Kramer, Rafaela; Erdmann, Michael; Schmitt, Christina; Heinzerling, Lucie; Abdou, Marie-Therese; Karbach, Julia; Schadendorf, Dirk; Zimmer, Lisa; Ugurel, Selma; Klümper, Niklas; ... (2023). Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y), 4(2), 113-129.e7. Cell Press 10.1016/j.medj.2022.12.007

Zander, Thilo; Pabst, Thomas; Schär, Sämi; Aebi, Stefan; Pabst, Tobias; Mey, Ulrich; Novak, Urban; Lerch, Erika; Rhyner, Gaëlle; Goede, Jeroen; Maniecka, Zuzanna; Hayoz, Stefanie; Rufer, Axel; Renner, Christoph; Driessen, Christoph (2021). P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study). Clinical lymphoma, myeloma and leukemia, 21(Suppl. 2), S165-S165. Elsevier 10.1016/S2152-2650(21)02354-5

Hoemme, Alexander; Barth, Holger; Haschke, Manuel Martin; Krähenbühl, Stephan; Strasser, Florian; Lehner, Claudia; von Kameke, Alexander; Wälti, Thomas; Thürlimann, Beat; Früh, Martin; Driessen, Christoph; Joerger, Markus (2019). Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer chemotherapy and pharmacology, 83(4), pp. 763-774. Springer 10.1007/s00280-019-03783-9

Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Driessen, Christoph; Duchosal, Michel A; Heim, Dominik; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Schmidt, Adrian; Taverna, Christian; Zander, Thilo; Renner, Christoph (2019). Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss medical weekly, 2019(149), pp. 1-8. EMH Media 10.4414/smw.2019.20031

Driessen, Christoph; Müller, Rouven; Novak, Urban; Cantoni, Nathan; Betticher, Daniel; Mach, Nicolas; Rüfer, Axel; Mey, Ulrich; Samaras, Panagiotis; Ribi, Karin; Besse, Lenka; Besse, Andrej; Berset, Catherine; Rondeau, Stephanie; Hawle, Hanne; Hitz, Felicitas; Pabst Müller, Thomas Niklaus; Zander, Thilo (2018). Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood, 132(19), pp. 2097-2100. American Society of Hematology 10.1182/blood-2018-05-851170

Driessen, Christoph; Kraus, Marianne; Joerger, Markus; Rosing, Hilde; Bader, Jürgen; Hitz, Felicitas; Berset, Catherine; Xyrafas, Alexandros; Hawle, Hanne; Berthod, Gregoire; Overkleeft, Hermann S; Sessa, Cristiana; Huitema, Alwin; Pabst, Thomas; von Moos, Roger; Hess, Dagmar; Mey, Ulrich J M (2016). Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica - the hematology journal, 101(3), pp. 346-355. Ferrata-Storti Foundation 10.3324/haematol.2015.135780

Mamot, Christoph; Klingbiel, Dirk; Hitz, Felicitas; Renner, Christoph; Pabst, Thomas; Driessen, Christoph; Mey, Ulrich; Pless, Miklos; Bargetzi, Mario; Krasniqi, Fatime; Gigli, Federica; Hany, Thomas; Samarin, Andrei; Biaggi, Christine; Rusterholz, Corinne; Dirnhofer, Stephan; Zucca, Emanuele; Martinelli, Giovanni (2015). Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). Journal of clinical oncology, 33(23), pp. 2523-2529. American Society of Clinical Oncology 10.1200/JCO.2014.58.9846

Stoeckle, Christina; Quecke, Paula; Rückrich, Thomas; Burster, Timo; Reich, Michael; Weber, Ekkehard; Kalbacher, Hubert; Driessen, Christoph; Melms, Arthur; Tolosa, Eva (2012). Cathepsin S dominates autoantigen processing in human thymic dendritic cells. Journal of autoimmunity, 38(4), pp. 332-43. Amsterdam: Elsevier 10.1016/j.jaut.2012.02.003

Stoeckle, Christina; Sommandas, Vinod; Adamopoulou, Eleni; Belisle, Kurt; Schiekofer, Stephan; Melms, Arthur; Weber, Ekkehard; Driessen, Christoph; Boehm, Bernhard O; Tolosa, Eva; Burster, Timo (2009). Cathepsin G is differentially expressed in primary human antigen-presenting cells. Cellular immunology, 255(1-2), pp. 41-5. San Diego, Calif.: Elsevier 10.1016/j.cellimm.2008.10.001

This list was generated on Fri Mar 29 07:50:31 2024 CET.
Provide Feedback